Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Herpesvirus 4, Human | 3 | 2019 | 387 | 1.22 | Why? |
| Epstein-Barr Virus Infections | 3 | 2019 | 366 | 1.15 | Why? |
| Hepatitis B | 5 | 2019 | 888 | 1.11 | Why? |
| DNA, Bacterial | 2 | 2018 | 835 | 1.08 | Why? |
| DNA, Viral | 7 | 2020 | 2521 | 0.98 | Why? |
| Hepatitis C | 5 | 2018 | 1514 | 0.89 | Why? |
| Latent Tuberculosis | 2 | 2018 | 324 | 0.86 | Why? |
| Jaundice | 2 | 2019 | 114 | 0.83 | Why? |
| AIDS Serodiagnosis | 2 | 2018 | 64 | 0.83 | Why? |
| Reagent Kits, Diagnostic | 3 | 2020 | 2149 | 0.81 | Why? |
| Sialic Acid Binding Ig-like Lectin 1 | 1 | 2021 | 156 | 0.81 | Why? |
| Miners | 1 | 2019 | 19 | 0.79 | Why? |
| Meningitis, Aseptic | 1 | 2018 | 22 | 0.76 | Why? |
| Mastitis | 1 | 2018 | 27 | 0.75 | Why? |
| Carboxylic Ester Hydrolases | 1 | 2018 | 16 | 0.74 | Why? |
| Dried Blood Spot Testing | 3 | 2018 | 383 | 0.74 | Why? |
| Leptospira | 1 | 2018 | 48 | 0.73 | Why? |
| Mycobacterium tuberculosis | 3 | 2019 | 1164 | 0.73 | Why? |
| Viral Core Proteins | 1 | 2018 | 134 | 0.72 | Why? |
| Hepatitis D | 1 | 2018 | 48 | 0.69 | Why? |
| Antibodies, Bacterial | 2 | 2018 | 510 | 0.68 | Why? |
| Tuberculosis, Meningeal | 1 | 2018 | 100 | 0.67 | Why? |
| Molecular Typing | 1 | 2018 | 280 | 0.67 | Why? |
| Leptospirosis | 1 | 2018 | 103 | 0.67 | Why? |
| Antibodies, Antinuclear | 1 | 2019 | 234 | 0.67 | Why? |
| Viremia | 3 | 2020 | 1020 | 0.67 | Why? |
| HIV-2 | 1 | 2017 | 92 | 0.66 | Why? |
| Sjogren's Syndrome | 1 | 2019 | 284 | 0.61 | Why? |
| Polymerase Chain Reaction | 5 | 2021 | 6740 | 0.59 | Why? |
| Herpes Simplex | 1 | 2018 | 272 | 0.58 | Why? |
| Antigens, Bacterial | 1 | 2018 | 330 | 0.57 | Why? |
| Syphilis | 1 | 2019 | 318 | 0.56 | Why? |
| Gold | 1 | 2019 | 592 | 0.55 | Why? |
| Hepacivirus | 3 | 2018 | 1509 | 0.55 | Why? |
| Virus Activation | 1 | 2019 | 480 | 0.55 | Why? |
| Substance Abuse, Intravenous | 1 | 2018 | 411 | 0.53 | Why? |
| Hepatitis B virus | 2 | 2019 | 882 | 0.50 | Why? |
| Bacterial Proteins | 2 | 2019 | 1318 | 0.48 | Why? |
| Tuberculosis | 2 | 2019 | 2895 | 0.47 | Why? |
| Enzyme-Linked Immunosorbent Assay | 4 | 2021 | 7868 | 0.47 | Why? |
| Burkina Faso | 4 | 2019 | 302 | 0.44 | Why? |
| Sputum | 1 | 2019 | 1720 | 0.42 | Why? |
| HIV Infections | 6 | 2018 | 11620 | 0.42 | Why? |
| HIV-1 | 4 | 2018 | 3365 | 0.40 | Why? |
| Seroconversion | 1 | 2020 | 2515 | 0.40 | Why? |
| Hepatitis B, Chronic | 1 | 2017 | 616 | 0.40 | Why? |
| Chimerism | 2 | 2018 | 10 | 0.37 | Why? |
| Monocytes | 1 | 2021 | 2978 | 0.36 | Why? |
| B-Lymphocytes | 3 | 2019 | 4418 | 0.36 | Why? |
| Sensitivity and Specificity | 13 | 2021 | 22971 | 0.35 | Why? |
| Hepatitis C Antibodies | 2 | 2018 | 120 | 0.34 | Why? |
| Serologic Tests | 5 | 2021 | 4359 | 0.32 | Why? |
| Point-of-Care Systems | 1 | 2020 | 2955 | 0.32 | Why? |
| Antibodies, Viral | 7 | 2021 | 51949 | 0.30 | Why? |
| Molecular Diagnostic Techniques | 2 | 2019 | 4239 | 0.30 | Why? |
| Antigens, Viral | 3 | 2021 | 6298 | 0.28 | Why? |
| Immunoassay | 3 | 2017 | 4485 | 0.27 | Why? |
| Clinical Laboratory Techniques | 4 | 2020 | 23402 | 0.25 | Why? |
| Real-Time Polymerase Chain Reaction | 3 | 2020 | 11367 | 0.22 | Why? |
| Milk, Human | 3 | 2018 | 956 | 0.21 | Why? |
| Limit of Detection | 2 | 2018 | 2698 | 0.21 | Why? |
| Exocrine Glands | 1 | 2019 | 2 | 0.21 | Why? |
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2019 | 9 | 0.20 | Why? |
| French Guiana | 1 | 2019 | 83 | 0.20 | Why? |
| RNA, Viral | 6 | 2019 | 32276 | 0.20 | Why? |
| Genotype | 4 | 2019 | 4697 | 0.20 | Why? |
| beta 2-Microglobulin | 1 | 2019 | 102 | 0.19 | Why? |
| Treponema pallidum | 1 | 2019 | 42 | 0.19 | Why? |
| Lymphocyte Depletion | 2 | 2020 | 293 | 0.19 | Why? |
| Retinal Pigment Epithelium | 1 | 2018 | 62 | 0.19 | Why? |
| Bacterial Load | 1 | 2019 | 179 | 0.18 | Why? |
| Cambodia | 1 | 2018 | 190 | 0.18 | Why? |
| Ribonucleoproteins | 1 | 2019 | 151 | 0.18 | Why? |
| Repetitive Sequences, Nucleic Acid | 1 | 2017 | 28 | 0.18 | Why? |
| Injections | 1 | 2018 | 237 | 0.17 | Why? |
| Herpesvirus 2, Human | 1 | 2018 | 137 | 0.17 | Why? |
| Adenovirus Infections, Human | 1 | 2019 | 145 | 0.17 | Why? |
| Undocumented Immigrants | 1 | 2019 | 100 | 0.17 | Why? |
| Adenoviruses, Human | 1 | 2019 | 195 | 0.17 | Why? |
| Blood-Brain Barrier | 1 | 2021 | 531 | 0.17 | Why? |
| Quality Control | 2 | 2017 | 628 | 0.16 | Why? |
| Vietnam | 2 | 2018 | 1665 | 0.16 | Why? |
| Autoantigens | 1 | 2019 | 388 | 0.16 | Why? |
| Adult | 15 | 2021 | 244371 | 0.16 | Why? |
| Serogroup | 1 | 2018 | 510 | 0.15 | Why? |
| Lymphocyte Activation | 2 | 2019 | 2742 | 0.15 | Why? |
| Immunologic Tests | 1 | 2018 | 445 | 0.15 | Why? |
| Hepatitis B Surface Antigens | 1 | 2017 | 305 | 0.15 | Why? |
| Herpesvirus 1, Human | 1 | 2018 | 286 | 0.15 | Why? |
| Drug Users | 1 | 2018 | 234 | 0.15 | Why? |
| Statistics, Nonparametric | 1 | 2018 | 1008 | 0.14 | Why? |
| Blotting, Western | 1 | 2017 | 863 | 0.14 | Why? |
| Hepatitis E | 1 | 2019 | 319 | 0.14 | Why? |
| Humans | 38 | 2021 | 930598 | 0.14 | Why? |
| Female | 20 | 2021 | 380317 | 0.13 | Why? |
| Immunoglobulin G | 5 | 2021 | 21571 | 0.13 | Why? |
| Viral Load | 4 | 2018 | 15850 | 0.13 | Why? |
| Male | 17 | 2021 | 367725 | 0.13 | Why? |
| Lipid Metabolism | 1 | 2018 | 572 | 0.13 | Why? |
| Reproducibility of Results | 3 | 2018 | 11304 | 0.13 | Why? |
| Smokers | 1 | 2019 | 550 | 0.13 | Why? |
| Flow Cytometry | 1 | 2021 | 2393 | 0.12 | Why? |
| Breast Feeding | 3 | 2018 | 1585 | 0.12 | Why? |
| Middle Aged | 12 | 2021 | 270681 | 0.11 | Why? |
| Early Diagnosis | 1 | 2021 | 2443 | 0.11 | Why? |
| Immunization | 1 | 2021 | 2019 | 0.11 | Why? |
| Infectious Mononucleosis | 1 | 2011 | 35 | 0.11 | Why? |
| ROC Curve | 2 | 2021 | 6024 | 0.11 | Why? |
| HIV | 1 | 2018 | 1116 | 0.11 | Why? |
| HIV Antibodies | 1 | 2017 | 776 | 0.11 | Why? |
| Endothelial Cells | 1 | 2021 | 2048 | 0.11 | Why? |
| Infectious Disease Transmission, Vertical | 2 | 2020 | 5164 | 0.10 | Why? |
| Biomarkers | 3 | 2021 | 23361 | 0.10 | Why? |
| Intestinal Mucosa | 1 | 2018 | 1046 | 0.10 | Why? |
| Cytokines | 1 | 2012 | 15010 | 0.10 | Why? |
| Taste Disorders | 1 | 2021 | 1720 | 0.10 | Why? |
| Nursing Homes | 3 | 2021 | 4155 | 0.10 | Why? |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 877 | 0.09 | Why? |
| Africa | 1 | 2018 | 2986 | 0.09 | Why? |
| Aged | 8 | 2021 | 215776 | 0.09 | Why? |
| Leukocytes, Mononuclear | 1 | 2018 | 2115 | 0.09 | Why? |
| Immune System | 1 | 2018 | 1479 | 0.09 | Why? |
| Health Personnel | 3 | 2020 | 29646 | 0.09 | Why? |
| BCG Vaccine | 1 | 2018 | 1137 | 0.09 | Why? |
| Adolescent | 6 | 2021 | 86841 | 0.09 | Why? |
| Diagnostic Tests, Routine | 1 | 2018 | 2643 | 0.08 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1573 | 0.08 | Why? |
| Immunoglobulin M | 2 | 2021 | 9091 | 0.08 | Why? |
| Interferons | 1 | 2018 | 2885 | 0.08 | Why? |
| Zika Virus | 1 | 2018 | 1924 | 0.08 | Why? |
| Immunologic Memory | 1 | 2018 | 3362 | 0.08 | Why? |
| France | 2 | 2021 | 12074 | 0.07 | Why? |
| Smoking | 1 | 2019 | 3358 | 0.07 | Why? |
| Zika Virus Infection | 1 | 2018 | 1920 | 0.07 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.07 | Why? |
| Vulnerable Populations | 1 | 2019 | 3099 | 0.07 | Why? |
| Brain | 1 | 2021 | 5133 | 0.07 | Why? |
| MicroRNAs | 1 | 2017 | 1787 | 0.07 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2021 | 13720 | 0.07 | Why? |
| Virus Replication | 2 | 2021 | 14331 | 0.06 | Why? |
| Olfaction Disorders | 1 | 2021 | 3704 | 0.06 | Why? |
| Disease Outbreaks | 2 | 2021 | 27595 | 0.06 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.06 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.06 | Why? |
| Young Adult | 4 | 2020 | 93724 | 0.06 | Why? |
| Fever | 1 | 2018 | 7795 | 0.05 | Why? |
| Rituximab | 2 | 2020 | 1096 | 0.05 | Why? |
| Anorexia | 1 | 2021 | 194 | 0.05 | Why? |
| Case-Control Studies | 1 | 2019 | 17671 | 0.05 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.05 | Why? |
| Prevalence | 2 | 2019 | 25773 | 0.05 | Why? |
| Seroepidemiologic Studies | 3 | 2020 | 10017 | 0.05 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.05 | Why? |
| Child | 2 | 2018 | 70012 | 0.05 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.05 | Why? |
| Hepatitis Antibodies | 1 | 2019 | 100 | 0.05 | Why? |
| Coinfection | 1 | 2018 | 6820 | 0.05 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2020 | 8843 | 0.04 | Why? |
| Cross Infection | 1 | 2020 | 8675 | 0.04 | Why? |
| Adenovirus Vaccines | 1 | 2019 | 103 | 0.04 | Why? |
| Gene Expression Regulation, Leukemic | 1 | 2017 | 31 | 0.04 | Why? |
| Cross-Sectional Studies | 3 | 2020 | 53120 | 0.04 | Why? |
| Phagocytosis | 1 | 2018 | 409 | 0.04 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.04 | Why? |
| Accidental Falls | 1 | 2021 | 448 | 0.04 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.04 | Why? |
| Maternal-Fetal Exchange | 1 | 2017 | 209 | 0.04 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.04 | Why? |
| Genes, env | 1 | 2015 | 17 | 0.04 | Why? |
| Lymphocytosis | 1 | 2017 | 122 | 0.04 | Why? |
| False Positive Reactions | 1 | 2021 | 1338 | 0.04 | Why? |
| Longitudinal Studies | 2 | 2021 | 9893 | 0.04 | Why? |
| Hepatitis E virus | 1 | 2019 | 306 | 0.04 | Why? |
| Likelihood Functions | 1 | 2017 | 719 | 0.04 | Why? |
| Homeostasis | 1 | 2018 | 582 | 0.04 | Why? |
| Genetic Therapy | 1 | 2019 | 409 | 0.03 | Why? |
| False Negative Reactions | 1 | 2021 | 1785 | 0.03 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2019 | 724 | 0.03 | Why? |
| Child Development | 1 | 2018 | 352 | 0.03 | Why? |
| RNA Interference | 1 | 2017 | 534 | 0.03 | Why? |
| Induced Pluripotent Stem Cells | 1 | 2018 | 584 | 0.03 | Why? |
| Epstein-Barr Virus Nuclear Antigens | 1 | 2011 | 7 | 0.03 | Why? |
| Cell Line, Tumor | 1 | 2021 | 3608 | 0.03 | Why? |
| Databases, Factual | 2 | 2017 | 6248 | 0.03 | Why? |
| alpha-Macroglobulins | 1 | 2011 | 17 | 0.03 | Why? |
| Genetic Vectors | 1 | 2019 | 1600 | 0.03 | Why? |
| Skilled Nursing Facilities | 1 | 2020 | 1098 | 0.03 | Why? |
| Pregnancy | 3 | 2018 | 23879 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2018 | 25144 | 0.03 | Why? |
| Sex Distribution | 1 | 2018 | 2083 | 0.03 | Why? |
| Fatal Outcome | 1 | 2020 | 3438 | 0.03 | Why? |
| Viral Tropism | 1 | 2018 | 1329 | 0.03 | Why? |
| Models, Biological | 2 | 2018 | 4907 | 0.03 | Why? |
| Trans-Activators | 1 | 2011 | 170 | 0.03 | Why? |
| Intersectoral Collaboration | 1 | 2017 | 1065 | 0.03 | Why? |
| Molecular Sequence Data | 1 | 2015 | 3198 | 0.02 | Why? |
| Self Report | 1 | 2021 | 3802 | 0.02 | Why? |
| Age Distribution | 1 | 2018 | 3567 | 0.02 | Why? |
| Cluster Analysis | 1 | 2017 | 3001 | 0.02 | Why? |
| Disease Reservoirs | 1 | 2017 | 1672 | 0.02 | Why? |
| Nucleocapsid Proteins | 1 | 2020 | 3120 | 0.02 | Why? |
| Biomarkers, Tumor | 1 | 2017 | 1314 | 0.02 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.02 | Why? |
| Residence Characteristics | 1 | 2018 | 1927 | 0.02 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.02 | Why? |
| Cells, Cultured | 1 | 2018 | 5835 | 0.02 | Why? |
| T-Lymphocytes, Cytotoxic | 1 | 2011 | 552 | 0.02 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.02 | Why? |
| Personnel, Hospital | 1 | 2020 | 2273 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2015 | 2830 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Immunotherapy | 1 | 2019 | 2421 | 0.02 | Why? |
| Patient Safety | 1 | 2020 | 4885 | 0.02 | Why? |
| Infant, Newborn | 2 | 2018 | 23105 | 0.02 | Why? |
| South Africa | 1 | 2015 | 3326 | 0.02 | Why? |
| Vero Cells | 1 | 2021 | 14117 | 0.02 | Why? |
| Occupational Health | 1 | 2020 | 3965 | 0.02 | Why? |
| Transcriptome | 1 | 2017 | 3466 | 0.02 | Why? |
| Infant | 2 | 2018 | 30274 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.01 | Why? |
| Mass Screening | 1 | 2021 | 8005 | 0.01 | Why? |
| Genetic Variation | 1 | 2015 | 3919 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2018 | 8495 | 0.01 | Why? |
| Animals | 2 | 2021 | 78931 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2019 | 7330 | 0.01 | Why? |
| Acute Disease | 1 | 2011 | 6029 | 0.01 | Why? |
| Age Factors | 1 | 2019 | 21039 | 0.01 | Why? |
| Incidence | 1 | 2019 | 25622 | 0.01 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.01 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.01 | Why? |
| Prospective Studies | 1 | 2021 | 43301 | 0.01 | Why? |
| Vaccination | 1 | 2019 | 19050 | 0.01 | Why? |
| Prognosis | 1 | 2017 | 32490 | 0.01 | Why? |
| United States | 1 | 2020 | 46150 | 0.01 | Why? |
| Viral Proteins | 1 | 2011 | 7370 | 0.01 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.01 | Why? |
| Treatment Outcome | 1 | 2017 | 51732 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.01 | Why? |
| Risk Factors | 1 | 2018 | 71621 | 0.01 | Why? |